What happened with LH today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Healthcare providers send patient specimens to Labcorp’s Diagnostics (Dx) laboratories for routine and specialized tests, including tissue analysis and genetic testing. This business supplies most of the company’s revenue and operates mainly in the United States. Labcorp bills insurers, ordering clients such as physicians and hospitals, Medicare and Medicaid, or patients; most insurer payments are fees for individual services. Revenue depends on test orders and the rates and coverage rules payers set. Its laboratories must maintain required licenses and certifications, including U.S. clinical laboratory certification under CLIA, to operate and bill payers.
Labcorp also serves drug developers through Biopharma Laboratory Services (BLS), its smaller business. Pharmaceutical and biotechnology companies pay it to carry out early-development work, such as safety testing, and to analyze, store and transport samples for clinical trials worldwide. These services provide laboratory data used in product development. BLS depends on customers’ research-and-development spending and their willingness to outsource work; customers can reduce or end many contracts when development programs change or stop.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Quest Diagnostics competes with Labcorp for routine and specialty tests ordered by physicians and hospitals, leaving both exposed to testing volumes and reimbursement. Watch Quest’s Advanced Diagnostics revenue: certain tests across five clinical areas exceeded $1 billion in 2025 with double-digit growth, showing the demand Labcorp faces in specialty testing.
Charles River Laboratories competes with Labcorp to help drug developers discover drugs and assess their safety before clinical trials, so both depend on pharmaceutical and biotechnology research budgets. Its Discovery and Safety Assessment revenue is the closest read on demand for work that overlaps with Labcorp’s early-development services.
IQVIA’s Q2 Solutions competes with Labcorp to perform laboratory testing for pharmaceutical companies’ clinical trials through their central laboratory businesses.
Myriad Genetics Inc competes with Labcorp in tests for hereditary cancer risk, pregnancy risks, inherited-condition carrier status and likely drug response. Watch its women’s-health and mental-health testing offerings for competition in prenatal and carrier screening and tests that help guide drug choices.
Natera competes with Labcorp in prenatal testing and carrier screening, with further overlap in cancer diagnostics. Its women’s-health tests, sold directly and through laboratory and distribution partners, are the clearest place to watch that competition.
NeoGenomics, Inc. competes with Labcorp for cancer testing and pathology work from physicians, hospitals and pharmaceutical companies. Its services that let community practices buy laboratory testing separately from expert interpretation show where clients can outsource work without building their own laboratory capabilities.
Thermo Fisher Scientific competes with Labcorp’s BLS business in laboratory services for drug developers, while its scientific products also depend on drug-development spending. Watch demand from pharmaceutical and biotechnology customers for its laboratory products and biopharma services, where that shared spending exposure is most direct.
Fortrea Holdings Inc. manages drug developers’ clinical trials while Labcorp supplies laboratory and early-development services, so both depend on trial funding and activity. Fortrea’s Clinical Services revenue is a useful read on spending by the pharmaceutical and biotechnology customers that also fund Labcorp’s drug-development work.
Tempus AI competes with Labcorp for cancer and hereditary testing ordered by healthcare providers. Its Diagnostics business, rather than its data-licensing business, is the direct place to watch competition for those testing orders.
Fulgent Genetics, Inc. competes with Labcorp in examining tissue, diagnosing genetic conditions and specialized cancer testing, earning laboratory revenue from testing and physician interpretation. Watch its laboratory-services business rather than therapeutic development for the overlap with Labcorp’s specialty diagnostics.
Guardant Health competes with Labcorp in blood- and tissue-based genetic tests that help physicians choose cancer therapies, with qualifying U.S. tests billed to Medicare and private insurers. Its oncology testing revenue is the relevant line to watch for that rivalry, rather than its separate screening business.
GeneDx Holdings Corp. competes with Labcorp’s genetic and genomic diagnostics through rare-disease testing, paid for by insurers, patients and healthcare clients. Its sequencing tests for rare and ultra-rare pediatric disorders are the concrete area to watch within that overlap.
Caris Life Sciences, Inc. and Labcorp compete to sell molecular cancer testing to treating physicians and biopharmaceutical customers. Caris’s tissue-based MI Profile and blood-based Caris Assure tests are the products to watch for competition in cancer profiling.
Quest Diagnostics Inc. earningsDGX
Quest Diagnostics’ report will show whether doctors and hospitals are ordering more advanced tests, where it competes directly with Labcorp’s specialty testing.
Compare Quest Diagnostics’ Advanced Diagnostics revenue and growth with the performance of its broader testing business. Faster growth in advanced tests would point to strong demand from doctors and hospitals, as well as tougher competition for Labcorp in specialty testing; slower advanced-test growth while the broader business holds up would suggest the pressure is concentrated in specialty tests, not testing overall. The takeaway is whether demand and competition in Labcorp’s specialty testing are strengthening or weakening in particular areas.
IQVIA Holdings Inc. earningsIQV
IQVIA’s report will show whether drug developers’ spending on clinical-trial lab testing is supporting growth at a direct competitor to Labcorp’s central laboratories.
Watch Q2 Solutions’ laboratory-services revenue and how it changes. Growth would show that drug developers are supporting demand for outsourced clinical-trial testing, and may also mean IQVIA is winning work Labcorp competes for; a decline could reflect slower trial activity or work shifting to competitors, which revenue alone cannot separate. The conclusion is whether Labcorp’s central laboratories face weaker overall demand or tougher competition for projects.
GeneDx Holdings Corp. earningsWGS
GeneDx Holdings Corp.’s report will show whether demand for rare-disease genetic testing is growing, an area where it competes with Labcorp’s specialty diagnostics.
Focus on GeneDx’s rare-disease testing revenue, especially sequencing for rare and ultra-rare pediatric disorders. Stronger revenue and growth would indicate expanding demand for these tests and tougher competition for Labcorp’s related genetic-testing work; slower growth would point to less momentum, though the report would need to clarify whether demand, insurance coverage or access to testing changed. The conclusion applies to rare-disease testing, not the whole genetic-testing market.
Labcorp Holdings Inc. earningsThis company
Labcorp’s report will show whether growth in diagnostic testing and biopharma laboratory services is also improving the business’s profitability.
Read Diagnostics testing volume and price/mix together, then check that segment’s margin. If both volume and price/mix improve and the margin rises, orders and revenue per test are both supporting profit; if either weakens and the margin falls, testing demand, reimbursement or service costs are weighing on the business. Then pair Biopharma Laboratory Services revenue with its margin: growth in both says drug-development work is converting into better operating results, while rising revenue but a falling margin says costs or the mix of work are offsetting growth. The conclusion is whether growth is backed by demand and sound economics, or constrained by pricing, reimbursement or costs.
NeoGenomics, Inc. earningsNEO
NeoGenomics, Inc.’s report will show whether doctors, hospitals and drug companies are sending more cancer testing and pathology work to outside labs, where it competes with Labcorp.
Watch NeoGenomics’ cancer-testing and pathology revenue, and whether community practices continue to outsource testing separately from expert interpretation. Rising revenue alongside stronger outsourcing would show that providers are sending more work to specialist labs: that expands the opportunity but also sharpens competition for Labcorp. Weakening revenue could mean slower outsourcing demand or difficulty winning orders. The takeaway is whether outsourced cancer testing is expanding or losing momentum in a competitive market.
Fortrea Holdings Inc. earningsFTRE
Fortrea Holdings Inc.’s clinical-services revenue will show whether drug developers are still running trials, the same customer activity that supports Labcorp’s biopharma services.
Watch whether Fortrea’s Clinical Services revenue grows or contracts, alongside its account of customer trial activity. Growth with broad trial activity would show that pharmaceutical and biotechnology customers are still spending on clinical development, supporting demand for Labcorp’s central-laboratory and trial-support services; a decline would signal a possible slowdown, but could also reflect project timing or Fortrea-specific execution. The conclusion is whether customer clinical-development spending is supporting Labcorp’s biopharma business.
Charles River Laboratories International, Inc. earningsCRL
Charles River Laboratories’ report will show whether drug developers’ spending supports discovery and preclinical safety work, where it competes with Labcorp’s early-development services.
Focus on revenue from Charles River Laboratories’ Discovery and Safety Assessment business, alongside what customers say about research budgets. Growth with improving customer spend would show that early-development and safety-assessment demand is holding up, but also that Labcorp faces a competitor winning work; a decline could reflect tighter budgets or Charles River-specific lost projects. The conclusion is whether the market for Labcorp’s early-development services is healthy and whether competitors are gaining ground.
Natera, Inc. earningsNTRA
Natera’s report will show whether demand for prenatal testing and carrier screening is growing, markets where its women’s-health tests compete with Labcorp’s genetic testing.
Watch Natera’s women’s-health testing revenue alongside its discussion of direct sales and partner channels. Growth would indicate expanding demand or reach for prenatal testing and carrier screening, while sharpening competition for Labcorp’s related genetic tests; weaker revenue would show less momentum, but would not by itself prove that the whole market is shrinking, since channel mix and market share also matter. The conclusion is whether this shared testing market is expanding or Natera’s business is losing momentum.
